Anti-arthritis and cancer drugs make it to COVID-19 drug trials

Experts are currently working on testing Izana Bioscience’s anti-arthritis, cancer drug- Namiluma, along with Infliximab and antitumour necrosis therapy to help in battling COVID-19.

The current novel pandemic does not seem to end anytime soon. Experts and scientists around the world, are reaching levels of desperation to find a vaccine or treatment for COVID-19. Currently, London based Universities Oxford University and Birmingham announced that they will be proceeding to clinical trials using a monoclonal antibody- Nalimuna used in treating rheumatoid arthritis, infliximab, and antitumor necrosis tumor therapy.

Experts believe severe cases of COVID-19 in patients, are known to be caused by an overreaction of the immune system, leading to a cytokine storm. The aim is to use the above anti-inflammatory drugs to see if they can help in arresting the virus.

Nalimuna a monoclonal antibody developed by Izana Biosciences is already in the last stages of its testing against the disease rheumatoid arthritis. The drug helps in targeting the cytokine GM-CSF when triggered is the reason for an excessive drug inflammation seen in severe COVID-19 cases.

The team states that “In the CATALYST study, we hope to show with a single dose of these kinds of drugs in hospitalized patients that we are able to delay or prevent the rapid deterioration into intensive care and requirement for invasive ventilation in this critical patient group.”

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit

Want to set up an online consultation for your practice, Click here